Related Experiment Video

Updated: Jan 16, 2026

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis
06:41

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

Published on: March 9, 2015

9.4K

A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform

Jonathan Mauer1, Chiara Whichello2, Brett Hauber1

  • 1Pfizer, New York, NY, USA.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|September 26, 2025
PubMed
Summary

Ritlecitinib 50 mg offers a favorable benefit-risk profile for alopecia areata (AA) patients, with most preferring it over placebo. This JAK3/TEC inhibitor shows potential for hair regrowth and improved quality of life.

Keywords:
alopecia areatapatient preferencequantitative benefit-risk analysisritlecitinib

More Related Videos

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

15.6K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.5K

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
407